SMITH J. JEFFERSON
Known title: Chief Research OfficerCIK: 0001770169
Associated companies
Transaction History
| DTIL | ▼ Sell | Open Market | 4,925 | $19K | 2/18/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 16,667 | $0 | 2/17/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 16,219 | — | 1/21/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 10,200 | $41K | 1/21/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 2,500 | — | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 10,447 | — | 1/20/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 154 | $756 | 3/4/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 519 | — | 3/3/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 10,287 | $49K | 1/22/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 29,168 | — | 1/20/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 50 | $590 | 6/10/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 163 | — | 6/7/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 833 | $10K | 5/8/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 154 | $2K | 5/2/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 519 | — | 5/1/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 1,006 | $12K | 2/29/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 28,000 | $10K | 1/23/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 75,015 | — | 1/20/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 5,175 | $2K | 8/31/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 4,872 | — | 6/7/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 15,576 | — | 3/3/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 12,157 | $12K | 2/28/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.